hrcak mascot   Srce   HID

Pregledni rad

ABNORMALITIES OF HEMOSTASIS IN PATIENTS WITH LIVER CIRRHOSIS

Matea Majerović
Ana Boban
Marina Premužić
Davor Radić
Ivana Knežević-Štromar
Agata Ladić
Željko Krznarić
Nadan Rustemović
Rajko Ostojić

Puni tekst: hrvatski, pdf (1 MB) str. 0-0 preuzimanja: 568* citiraj
APA 6th Edition
Majerović, M., Boban, A., Premužić, M., Radić, D., Knežević-Štromar, I., Ladić, A., ... Ostojić, R. (2016). POREMEĆAJI HEMOSTAZE U BOLESNIKA S CIROZOM JETRE. Liječnički vjesnik, 138 (9-10), 0-0. Preuzeto s https://hrcak.srce.hr/172890
MLA 8th Edition
Majerović, Matea, et al. "POREMEĆAJI HEMOSTAZE U BOLESNIKA S CIROZOM JETRE." Liječnički vjesnik, vol. 138, br. 9-10, 2016, str. 0-0. https://hrcak.srce.hr/172890. Citirano 19.10.2019.
Chicago 17th Edition
Majerović, Matea, Ana Boban, Marina Premužić, Davor Radić, Ivana Knežević-Štromar, Agata Ladić, Željko Krznarić, Nadan Rustemović i Rajko Ostojić. "POREMEĆAJI HEMOSTAZE U BOLESNIKA S CIROZOM JETRE." Liječnički vjesnik 138, br. 9-10 (2016): 0-0. https://hrcak.srce.hr/172890
Harvard
Majerović, M., et al. (2016). 'POREMEĆAJI HEMOSTAZE U BOLESNIKA S CIROZOM JETRE', Liječnički vjesnik, 138(9-10), str. 0-0. Preuzeto s: https://hrcak.srce.hr/172890 (Datum pristupa: 19.10.2019.)
Vancouver
Majerović M, Boban A, Premužić M, Radić D, Knežević-Štromar I, Ladić A i sur. POREMEĆAJI HEMOSTAZE U BOLESNIKA S CIROZOM JETRE. Liječnički vjesnik [Internet]. 2016 [pristupljeno 19.10.2019.];138(9-10):0-0. Dostupno na: https://hrcak.srce.hr/172890
IEEE
M. Majerović, et al., "POREMEĆAJI HEMOSTAZE U BOLESNIKA S CIROZOM JETRE", Liječnički vjesnik, vol.138, br. 9-10, str. 0-0, 2016. [Online]. Dostupno na: https://hrcak.srce.hr/172890. [Citirano: 19.10.2019.]

Sažetak
Until the beginning of the 90ies, it was believed that patients with liver cirrhosis were auto-anticoagulated and thus protected from thromboembolic events. However, new discoveries have broken the longstanding paradigm. In deranged hepatic function there is a reduced synthesis of procoagulants and endogenous anticoagulants, however, extrahepatally synthesized hemostatic and fibrinolytic factors are disproportionately affected. In stable disease hemostatic system is ”rebalanced’’ but fragile, therefore, even a minimal stress can promote bleeding or thrombosis. Also, there are many concomitant factors, such as hemodynamic changes, other organ affection, namely kidney, and predisposition to infection, that shift the balance towards either bleeding or thrombosis. Conventional laboratory tests are not sufficient for evaluation of the bleeding risk, prothrombotic risk factors are not clearly identified, and safety profile of antithrombotic drugs is not precisely evaluated since cirrhotic patients are mainly excluded from big clinical trials. For all that is said, the diagnostic and therapeutic approach in this context is complex and requires teamwork of a hepatologist, hematologist and in a phase of operative treatment, the anesthesiologist. In this review article, we will discuss mechanisms of hemostatic and fibrinolytic abnormalities of liver cirrhosis, the incidence of thromboembolic events as well as prophylactic and therapeutic options in the setting of conservative treatment.

Ključne riječi
Liver cirrhosis – blood, complications, physiopathology, drug therapy; Blood coagulation disorders – etiology, diagnosis, complications, drug therapy; Blood coagulation tests – methods; Hemostasis; Fibrinolysis; Venous thromboembolism – etiology, drug therapy, prevention and control; Hemorrhage – etiology, prevention and control; Anticoagulants – therapeutic use, adverse effects; Blood component transfusion

Hrčak ID: 172890

URI
https://hrcak.srce.hr/172890

[hrvatski]

Posjeta: 771 *